Anixa Biosciences, Inc. (NASDAQ:ANIX) Short Interest Down 28.9% in October

Anixa Biosciences, Inc. (NASDAQ:ANIX) was the target of a significant drop in short interest in the month of October. As of October 31st, there was short interest totalling 421,900 shares, a drop of 28.9% from the October 15th total of 593,700 shares. Approximately 1.4% of the company’s stock are sold short. Based on an average daily trading volume, of 75,800 shares, the short-interest ratio is presently 5.6 days.

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on ANIX shares. HC Wainwright reissued a “buy” rating and set a $7.00 price target on shares of Anixa Biosciences in a research report on Tuesday, September 17th. EF Hutton Acquisition Co. I raised shares of Anixa Biosciences to a “strong-buy” rating in a research note on Wednesday, August 7th.

Anixa Biosciences Price Performance

Shares of ANIX stock opened at $3.08 on Friday. The firm has a market cap of $99.11 million, a P/E ratio of -7.90 and a beta of 0.84. The stock’s 50-day moving average is $3.26 and its two-hundred day moving average is $2.99. Anixa Biosciences has a fifty-two week low of $2.14 and a fifty-two week high of $5.13.

Anixa Biosciences (NASDAQ:ANIX) last released its quarterly earnings results on Friday, September 6th. The company reported ($0.10) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.01. As a group, research analysts expect that Anixa Biosciences will post -0.42 EPS for the current year.

Institutional Trading of Anixa Biosciences

Several large investors have recently made changes to their positions in the stock. Tyler Stone Wealth Management raised its position in shares of Anixa Biosciences by 100.0% in the third quarter. Tyler Stone Wealth Management now owns 42,016 shares of the company’s stock valued at $132,000 after purchasing an additional 21,008 shares during the period. International Assets Investment Management LLC lifted its position in Anixa Biosciences by 170.0% during the 3rd quarter. International Assets Investment Management LLC now owns 37,800 shares of the company’s stock worth $1,190,000 after acquiring an additional 23,800 shares during the last quarter. Nations Financial Group Inc. IA ADV boosted its holdings in Anixa Biosciences by 50.0% during the second quarter. Nations Financial Group Inc. IA ADV now owns 22,500 shares of the company’s stock valued at $50,000 after acquiring an additional 7,500 shares during the period. Virtu Financial LLC grew its position in shares of Anixa Biosciences by 47.2% in the first quarter. Virtu Financial LLC now owns 16,156 shares of the company’s stock valued at $50,000 after purchasing an additional 5,183 shares during the last quarter. Finally, Concorde Asset Management LLC bought a new position in shares of Anixa Biosciences in the second quarter worth about $31,000. Institutional investors own 29.13% of the company’s stock.

About Anixa Biosciences

Anixa Biosciences, Inc, a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer.